Human Kallikrein 2: A Novel Lineage-Specific Surface Target in Prostate Cancer.

ABSTRACT:

Purpose

Targeted therapies for metastatic prostate cancer are limited, highlighting the need for novel drug targets and mechanisms of action (MoA). Human kallikrein 2 (KLK2) is a prostate-specific antigen expressed across the prostate cancer disease continuum. However, it was not recognized as a therapeutic target for prostate cancer in the past due to limited evidence of its cell surface expression. In this study, we systematically characterized KLK2 expression in prostate cancer, confirmed its cell surface expression, and demonstrated the preclinical efficacy of three KLK2-targeting therapeutics with distinct MoA.

Experimental design

The KLK2 expression profile in different stages of prostate cancer and its cell surface expression were confirmed by IHC and multiplex immuno

SUBMITTER: Shen F 

PROVIDER: S-EPMC12580770 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature